SkyePharma transfers E.U. Solaraze rights to Shire, acquires Bioglan's drug delivery business May 15, 2002
Potential efficacy of the selective proteasome inhibitor PS-519 as a treatment for psoriasis May 3, 2002
MorphoSys details change in strategy, describes first proprietary therapeutic antibody candidates April 25, 2002
RSS